ANI Pharmaceuticals, Inc.
ANIP
$82.72
-$0.05-0.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 37.03% | 43.78% | 48.87% | 38.68% | 30.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.03% | 43.78% | 48.87% | 38.68% | 30.26% |
| Cost of Revenue | 38.91% | 44.25% | 41.26% | 36.79% | 35.00% |
| Gross Profit | 35.85% | 43.49% | 53.86% | 39.83% | 27.45% |
| SG&A Expenses | 20.66% | 36.76% | 41.67% | 58.88% | 50.10% |
| Depreciation & Amortization | 17.79% | 34.97% | 51.52% | 41.38% | 27.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.40% | 38.00% | 43.09% | 45.85% | 37.91% |
| Operating Income | 224.39% | 142.73% | 166.32% | -29.48% | -37.33% |
| Income Before Tax | 520.99% | 531.26% | 773.73% | -141.54% | -164.03% |
| Income Tax Expenses | 466.66% | 573.01% | 2,522.09% | -153.42% | -186.88% |
| Earnings from Continuing Operations | 537.80% | 522.94% | 672.15% | -137.80% | -159.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 537.80% | 522.94% | 672.15% | -137.80% | -159.21% |
| EBIT | 224.39% | 142.73% | 166.32% | -29.48% | -37.33% |
| EBITDA | 80.33% | 70.93% | 86.12% | 8.65% | -3.09% |
| EPS Basic | 452.16% | 439.90% | 489.11% | -158.09% | -171.36% |
| Normalized Basic EPS | 699.71% | 394.72% | 640.90% | -51.78% | -64.30% |
| EPS Diluted | 434.12% | 422.18% | 458.77% | -160.92% | -173.56% |
| Normalized Diluted EPS | 683.14% | 381.50% | 645.61% | -52.77% | -64.47% |
| Average Basic Shares Outstanding | 4.80% | 3.79% | 2.78% | 2.60% | 4.16% |
| Average Diluted Shares Outstanding | 8.31% | 7.25% | 4.56% | 2.74% | 3.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.11% | 1.17% | 1.17% | -3.65% | -2.69% |